ForPatients
by Roche

Idiopathic Pulmonary Fibrosis (IPF)

Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Trial Status	Trial Runs In	Trial Identifier
Completed	8 Countries	NCT02598193 2015-003280-11 MA29895

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF. Eligible participants must have received pirfenidone for at least 16 weeks on a stable dose. Nintedanib will be added on Day 1 of the study as a combination treatment for IPF for 24 weeks.

Hoffmann-La Roche	Phase 4
Sponsor	Phase

NCT02598193 2015-003280-11 MA29895
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 40 Years & <= 80 Years	No